Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Institution of Radiotherapy & Oncology

1 abstract

Abstract
A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors.
Org: Second Affiliated Hospital of Soochow University, Institution of Radiotherapy & Oncology, Soochow University,